Inhibition and induction of CYP enzymes in humans: an update
The cytochrome P450 (CYP) enzyme family is the most important enzyme system catalyzing
the phase 1 metabolism of pharmaceuticals and other xenobiotics such as herbal remedies …
the phase 1 metabolism of pharmaceuticals and other xenobiotics such as herbal remedies …
Physiologically based pharmacokinetic (PBPK) model-informed dosing guidelines for pediatric clinical care: a pragmatic approach for a special population
JJM Freriksen, JEM van der Heijden… - Pediatric Drugs, 2023 - Springer
Physiologically based pharmacokinetic (PBPK) modeling can be an attractive tool to
increase the evidence base of pediatric drug dosing recommendations by making optimal …
increase the evidence base of pediatric drug dosing recommendations by making optimal …
Verification of a cocktail approach for quantitative drug–drug interaction assessment: A comparative analysis between the results of a single drug and a cocktail drug
M Miura, S Uchida, S Tanaka, C Kamiya… - Xenobiotica, 2021 - Taylor & Francis
A cocktail approach is a method to comprehensively evaluate the activity of cytochrome
P450 enzymes (CYPs) by co-administering multiple CYP substrates. This is the first report …
P450 enzymes (CYPs) by co-administering multiple CYP substrates. This is the first report …
Pharmacokinetics, safety, and tolerability of rolapitant administered intravenously following single ascending and multiple ascending doses in healthy subjects
X Wang, ZY Zhang, J Wang, D Powers… - … in drug development, 2019 - Wiley Online Library
Rolapitant is a selective and long‐acting neurokinin‐1 receptor antagonist approved in an
oral formulation in combination with dexamethasone and a 5‐hydroxytryptamine type 3 …
oral formulation in combination with dexamethasone and a 5‐hydroxytryptamine type 3 …
An Open‐Label, Randomized, Pivotal Bioequivalence Study of Oral Rolapitant
ZY Zhang, J Wang, S Arora, S Lu… - Clinical …, 2019 - Wiley Online Library
Rolapitant, a selective and long‐acting neurokinin‐1 receptor antagonist, is approved in an
oral formulation for prevention of delayed chemotherapy‐induced nausea and vomiting in …
oral formulation for prevention of delayed chemotherapy‐induced nausea and vomiting in …
Extrapolation of pharmacokinetic interaction data of proton pump inhibitors obtained in healthy subjects for oral targeted therapies in cancer patients
NR Srinivas - International Journal of Pharmacokinetics, 2018 - Taylor & Francis
During the drug-development process, it is essential to evaluate the potential for any drug–
drug interaction (DDI) during early clinical Phase I stage based on the in vitro absorption …
drug interaction (DDI) during early clinical Phase I stage based on the in vitro absorption …
Population Pharmacokinetics of Rolapitant in Patients With Chemotherapy‐Induced Nausea and Vomiting
X Wang, J Wang, ZY Zhang… - Clinical Pharmacology in …, 2019 - Wiley Online Library
Population pharmacokinetics of rolapitant and its active metabolite M19 were studied in 482
patients receiving this neurokinin‐1 receptor antagonist in combination with a 5 …
patients receiving this neurokinin‐1 receptor antagonist in combination with a 5 …
[PDF][PDF] シトクロムP450 活性及び薬物相互作用の評価を目的とした臨床試験法に関する研究
三浦基靖 - 2021 - u-shizuoka-ken.repo.nii.ac.jp
CE Collision energy (コリジョンエネルギー) CL Clearance (クリアランス) CLobse Observed
value of clearance (クリアランスの実測値) CLpred Predictied value of clearance …
value of clearance (クリアランスの実測値) CLpred Predictied value of clearance …